Beckman, Recognizing Inverness' Bid for Biosite, Extends Own Offer Deadline | GenomeWeb
NEW YORK (GenomeWeb News) — Beckman Coulter today said it has extended its offer to buy Biosite to May 2, which the day that a counteroffer by Inverness Medical Innovations runs out.
 
Late last week, Biosite told Beckman Coulter that it “currently intends” to accept a rival offer from Inverness, which proposes to buy the company for $90 a share. Beckman’s original offer, made in March, was for $85 a share.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.